Morgan Stanley analyst Terence Flynn upgraded Vertex Pharmaceuticals (VRTX) to Overweight from Equal Weight with a price target of $516, up from $438. The firm is taking a more positive stance on the company’s kidney franchise pipeline, including Pove and Inaxaplin. If the drugs are successful in Phase 3, with key data coming in 2026, they will accelerate Vertex’s earnings and revenue growth and drive diversification away from cystic fibrosis, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
- Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
- Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025